Proposed Controlled Substances Regulations

Summary#

The government is proposing new Controlled Substances Regulations (CSR) to replace and combine several older rules that govern legal uses of opioids, stimulants, benzodiazepines, psychedelics and related products. Health Canada says the goal is to simplify and harmonize rules (for example, for pharmacies, licensed dealers and researchers), while keeping controls to reduce diversion to the illegal market.

What it does#

• Consolidates the Narcotic Control Regulations, the Benzodiazepines and Other Targeted Substances Regulations, Parts G and J of the Food and Drug Regulations, the New Classes of Practitioners Regulations, and several class exemptions into one set: the proposed Controlled Substances Regulations (CSR).
• Harmonizes and updates authorizations and record-keeping across all categories of controlled substances.
• Changes affecting pharmacies and staff:
  • Lets pharmacy technicians independently carry out many tasks now done only by pharmacists (compounding, sending, transporting, destroying and similar activities).
  • Allows pharmacists to sell or provide controlled-substance prescriptions to another pharmacist for routine (non-emergency) “central fill” services without the pharmacy holding a dealer’s licence.
• Travel and personal possession:
  • Authorizes individuals to import or export prescribed medicines that contain controlled substances for personal medical use up to a 90-day supply (up from 30 days for some categories).
• Reporting and record changes:
  • Licensed dealers would file monthly activity reports (to reflect current practice) rather than annual reports.
  • Unexplainable losses would be reported to Health Canada (not to police); actual thefts would still be reported to both police and Health Canada.
  • New record fields are required in some cases (for example, recording the drug identification number — DIN — for prescription drugs containing cannabis or other controlled substances).
• Research and test kits:
  • Removes the separate Part J research authorization for restricted drugs; researchers would use the existing exemption pathway instead (removing one required institutional support letter).
  • Simplifies test-kit changes: holders would notify the regulator instead of reapplying for a new registration when making certain modifications. Test kits that are no longer regulated as medical devices could still be sold under the CSR rules.
• Licensing and security updates:
  • Minor modernization, e.g., allowing RCMP-accredited fingerprinting services for criminal record checks, and adding more shipping detail to import/export permit applications.
• Schedules and substance changes:
  • Proposes adding two synthetic opioids to the narcotics schedule: bezitramide and piritramide.
  • Proposes removing some outdated or unused restrictions (for example, certain limits on diacetylmorphine would be lifted, while keeping limits for midwives and podiatrists).
• Timing and process:
  • This is a proposal (Canada Gazette, Part I). Comments are invited for 60 days after publication. The rules, if finalized, would come into force 365 days after they are published in Canada Gazette, Part II.
• Cost/benefit summary (government estimate):
  • Over 10 years, estimated monetized benefits $4.85 million (PV) and costs $4.09 million (PV), for a net benefit of $0.76 million (PV).

Who's affected#

• Health Canada and other federal agencies that administer and inspect controlled-substance activities.
• Pharmacies and pharmacy staff, including pharmacists and pharmacy technicians (scope and record-keeping changes).
• Licensed dealers (producers, importers/exporters, distributors) and cannabis licence holders.
• Practitioners (doctors, dentists, veterinarians, nurse practitioners, midwives, podiatrists) and hospitals.
• Researchers using restricted drugs and holders of test-kit registration numbers.
• Individuals who travel with prescription medicines.
• Provincial/territorial governments and professional licensing authorities (they may need to update rules and guidance).
• Small businesses in the sector: the government estimates about 98% of affected businesses are small businesses. The department estimates total small-business compliance costs of $2.35 million (PV) over 10 years, but an overall net saving to small businesses of $0.91 million (PV) across the same period.
  If any part of who will be affected is unclear in the proposal, Health Canada asks for feedback during the consultation period.

Why it matters#

• It aims to make the rules clearer and easier to follow. That should reduce confusion and administrative burden for pharmacies, dealers and Health Canada.
• Practical benefits for patients and travellers: carrying up to a 90-day supply of prescribed controlled medications makes travel easier, especially for people with chronic conditions or travelling with an animal.
• It supports pharmacy practice changes that many stakeholders have asked for, like enabling central fill services and letting trained pharmacy technicians do more independently. That could speed up pharmacy operations and lower costs.
• Researchers may face less paperwork for some restricted-drug studies (one fewer required institutional letter).
• There are trade-offs: some parties will face new or expanded record-keeping and notification duties while everyone adjusts to the new consolidated rules. The government’s analysis estimates modest net benefits overall, but there will be transition costs and some ongoing compliance costs.
• This is a proposed rule, not yet law. Comments are open for 60 days; the changes would take effect only if the regulations are finalized and then published in Part II (with a 365-day delay to give parties time to adapt).